Moreover, aberrant expressions of IFITM1 detected through cancer array profiling, immunohistochemistry, RT-PCR, immunoblotting, and immunofluorescence analysis were verified in colorectal cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma (HNSCC), gallbladder, and ovarian cancer (6, 8, 23, 44–46). Here, IFITM1 is linked to head and neck squamous cell carcinoma.